News About: Pharm. Affairs
Endless fair racing enforcement issues, “The problem is international symposium”
The pharmaceutical industry’s fair racing enforcement is getting tighter, the issue with lecture fees and international symposiums is categorized as a field which has not been addressed.
Particularly, the one with ‘i...
Court, “Dong-A ST’s first Baraclude generic did not infringe patent right”
The court raised a hand of Dong-A ST at the patent infringement trial of ‘Baraclude’ between BMS and Dong-A ST.
It means ‘Baracle,’ a generic launched by Dong-A ST did not infringe the Baraclude’s substance patent.
...
Handok introduced Actelion’s pulmonary hypertension therapy, ‘Opsumit’
Handok(President Young-jin Kim) launched a new Actelion’s pulmonary hypertension therapy, ‘Opsumit Tab 10mg(generic name: macitentan, hereinafter referring to Opsumit),’ in Korea.
After launching ‘Tracleer’ developed...
Gilead’s ‘Truvada’ positioned at top in domestic HIV treatment market
The Gilead Sciences’ HIV therapy, Truvada, was observed to maintain the top position in the domestic HIV market.
According to the IMS Health DATA on the 8th, the Truvada backbone treatment’s market share in the dome...
Urologists complex for complexes, “No on Amolafil’s insurance benefit”
While the Hanmi Pharm’s erectile dysfunction and hypertension complex, Amolafil, has been approved by the Ministry of Food and Drug Safety, the medical field has raised concerns.
The field indicated if complexes wit...
SK’s pneumococcal conjugate vaccine to be discussed at Central Pharmacists Deliberation Committee
The government will hold the Central Pharmacists Deliberation Committee over the conditional approval and clinical trials of the 13-valent pneumococcal conjugate vaccine that are being developed by SK Chemicals.
The...
Hyundai Pharm lost Yaz’s patent conflict against leading contraceptive company
Hyundai Pharm, a company owning the largest market share in the morning-after pill market, lost the patent conflict which attracted attention of the industry since it was against the leading company in birth control p...
‘Swift Evaluation’ on new drugs approved for the first time in Korea
The government will push forward with a measure for newly-approved new drugs for the first time in Korea to pass insurance benefit propriety evaluations within 100 days in Korea. It has decided to introduce the so-cal...
FKI, “Attracting global companies is the key to success in the biopharmaceutical field”
The Federation of Korean Industries(FKI) proposed policy support measures for the government to foster the biopharmaceutical industry at the Ministry of Strategy and Finance on the 2nd.
Introducing successful cases o...
Prescription of obesity treatment, ‘Contrave’ started, competing against ‘Belviq’
Since the prescription of ‘Contrave(naltrexone+bupropion),’ an obesity therapy whose domestic exclusive sales agreement was established by Kwang Dong Pharmaceutical, started this month, interests have been focused on ...
